Advance online publication
The latest papers brought to you ahead of print publication by Nature Clinical Practice. Advance online publication papers are listed below.
About advance online publication
Practice Points
Combined transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma
Published online:
19 August 2008
doi:10.1038/ncponc1216 |
Full Text | PDF (163K)
Should surgery followed by whole-brain radiation therapy be the standard treatment for single brain metastasis?
Published online:
12 August 2008
doi:10.1038/ncponc1217 |
Full Text | PDF (159K)
The ROC 'n' role of the multiplex assay for early detection of ovarian cancer
Published online:
12 August 2008
doi:10.1038/ncponc1214 |
Full Text | PDF (164K)
VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia
Published online:
22 July 2008
doi:10.1038/ncponc1202 |
Full Text | PDF (82K)
Early postinduction intensification therapy is essential in childhood acute lymphoblastic leukemia
Published online:
22 July 2008
doi:10.1038/ncponc1184 |
Full Text | PDF (168K)
Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
Published online:
22 July 2008
doi:10.1038/ncponc1201 |
Full Text | PDF (167K)
Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer?
Published online:
15 July 2008
doi:10.1038/ncponc1200 |
Full Text | PDF (159K)
Viewpoints
The rationale for sentinel-node biopsy in primary melanoma
The value of sentinel-node biopsy for the management of localized primary melanoma has been questioned. In this Viewpoint, the authors discuss the data that support the routine use of sentinel-node biopsy, and assert why this technique should be considered the standard approach for staging patients with clinically localized, intermediate-thickness melanoma.
Published online:
05 August 2008
doi:10.1038/ncponc1205 |
Full Text | PDF (168K)
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
Over 80% of men with advanced prostate cancer respond to standard treatment with continuous androgen deprivation therapy. Most of these patients, however, go on to develop androgen resistance and disease progression. The authors of this Viewpoint propose that intermittent androgen deprivation should be the standard therapy in advanced prostate cancer.
Published online:
15 July 2008
doi:10.1038/ncponc1180 |
Full Text | PDF (175K)
Reviews
Response criteria for glioma
The current method for assessing response to therapy of glial tumors is based on the Macdonald et al. criteria; however, these criteria are ambiguous in key features such as the appropriate threshold for lesion size and the actual methods for applying the stated criteria. The authors of this Review identify the strengths and shortcomings of the current approach and also discuss technological advances in both drug therapy and imaging that necessitate reassessment of the Macdonald et al. criteria.
Published online:
19 August 2008
doi:10.1038/ncponc1204 |
Full Text | PDF (647K)
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies
Technologies such as mass spectrometry, and protein and DNA arrays, have enabled simultaneous examination of thousands of proteins and genes, giving opportunities to identify distinguishing signatures for cancer diagnosis and classification and prediction of therapeutic response. The authors provide an overview of how the current cancer biomarkers were discovered and their associated limitations, discuss the utilization of these emerging technologies, and review their potential to revolutionize biomarker discovery.
Published online:
12 August 2008
doi:10.1038/ncponc1187 |
Full Text | PDF (666K)
Treatment of Hodgkin lymphoma: the past, present, and future
Our understanding of the biology of Hodgkin's lymphoma has improved, in particular the genetic and phenotypic characteristics of malignant cells and the signaling pathways involved in the pathogenesis of this disease. While newer regimens have improved the cure rates of patients with Hodgkin's lymphoma, some are associated with severe acute and long-term toxicities. This comprehensive Review discusses combined modality regimens for treating early-stage disease, approaches used for treating advanced disease and other novel regimens.
Published online:
05 August 2008
doi:10.1038/ncponc1186 |
Full Text | PDF (505K)
Gene-expression profiling in epithelial ovarian cancer
In epithelial ovarian cancer, gene-expression profiling has been used to provide prognostic information, to predict response to first-line platinum-based chemotherapy, and to discriminate between different histologic subtypes. The authors of this Review summarize the contributions of gene-expression profiling to the diagnosis and management of epithelial ovarian cancer and discuss ways in which this technique could become a useful tool in clinical management.
Published online:
22 July 2008
doi:10.1038/ncponc1178 |
Full Text | PDF (620K)
Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers
Our understanding of the pathogenesis of tobacco-related lung carcinogenesis is improving but the molecular mechanisms of neoplastic transformation in never-smokers have not yet been elucidated. Mountzios et al. describe the best characterized signaling pathways that are implicated in the transduction of proliferative signals, and discuss the differences in the molecular characteristics of smokers and never-smokers.
Published online:
15 July 2008
doi:10.1038/ncponc1181 |
Full Text | PDF (333K)
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC
Mammalian target of rapamycin (mTOR) is an important and clinically relevant therapeutic target. Temsirolimus has significantly improved overall survival rates in patients with advanced renal cell carcinoma, thereby validating the importance of mTOR in the natural history of this disease. This Review discusses the clinical development of temsirolimus, its novel mechanism of action, and the investigational strategies for targeting mTOR in other tumor types.
Published online:
08 July 2008
doi:10.1038/ncponc1173 |
Full Text | PDF (366K)
The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2
Estrogen-deprivation strategies with aromatase inhibitors are superior to tamoxifen in the adjuvant, neoadjuvant and advanced breast-cancer settings in postmenopausal patients. Short-term hormonal resistance especially in the HER2-positive patient population, however, is a significant issue with these endocrine agents. The authors discuss the progress made in our understanding of resistance to endocrine therapy, and provide insights regarding the management of patients with hormone receptor-positive/HER2-positive advanced breast cancer.
Published online:
08 July 2008
doi:10.1038/ncponc1179 |
Full Text | PDF (461K)
Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer
There are few treatment options for patients with metastatic HER2-positive breast cancer who are unresponsive to trastuzumab. The combination of lapatinib and capecitabine significantly prolongs time to disease progression in women previously treated with chemotherapy and trastuzumab for HER2-positive advanced disease. The rationale for using this combination and the promising activity of lapatinib in early trials of inflammatory breast cancer is highlighted.
Published online:
01 July 2008
doi:10.1038/ncponc1156 |
Full Text | PDF (344K)
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications
It is unlikely that tumors are entirely dependent on only one abnormally activated signaling pathway and, consequently, treatment with an agent interfering with a single target may be insufficient. This Review discusses the experimental and early-stage clinical evidence to support the relevance of EGFR-dependent and VEGF-dependent pathways, their functional links and the implications of acquired resistance to targeted therapies.
Published online:
01 July 2008
doi:10.1038/ncponc1161 |
Full Text | PDF (343K)
Case Study
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
The prognosis for patients with advanced melanoma and CNS metastases is poor. Hodi et al. report the case of a 63-year-old female who was diagnosed with metastatic melanoma from an unknown primary tumor. The authors discuss the use of the human monoclonal antibody against CTLA-4, ipilimumab, in patients with metastatic melanoma.
Published online:
29 July 2008
doi:10.1038/ncponc1183 |
Full Text | PDF (806K)
Top of page
Until print versions of AOP papers are published, they should be cited in the style "Authorname A et al. (year) Title of article. Nat Clin Pract Oncol, advance online publication, day month year [doi:10.1038/ncponcxxxx]". Once the print version (identical to the AOP) is published, it should be cited as follows: "Authorname A et al. (year) Title of article. Nat Clin Pract Oncol Vol: xxx–xxx, advance online publication, [doi:10.1038/ncponcxxxx]".
